Caspase-8 and FLIP regulate RIG-I/MDA5-induced innate immune host responses to picornaviruses

Future Virology

Volumn 7, Issue 12, 2012, Pages 1221-1236

  Buskiewicz, Iwona A ^a   Koenig, Andreas ^b   Huber, Sally A ^a   Budd, Ralph C ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

apoptosis; caspase 8; FLIP; innate immunity; MAVS; MDA5; mitochondria; picornavirus; RIG I

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN; INTERFERON; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I;

5' UNTRANSLATED REGION; BINDING SITE; CELL SPECIFICITY; COXSACKIE VIRUS; ENCEPHALOMYOCARDITIS VIRUS; FLAVIVIRUS; GENE EXPRESSION; GENE REPLICATION; HELA CELL; HUMAN; IMMUNE RESPONSE; INFLUENZA; INNATE IMMUNITY; NECROPTOSIS; NONHUMAN; PARAMYXOVIRUS; PICORNAVIRUS; PICORNAVIRUS INFECTION; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHABDOVIRUS; RHINOVIRUS; RNA VIRUS; SIGNAL TRANSDUCTION; VIRION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALIA; PICORNAVIRIDAE; RNA VIRUSES;

EID: 84871220377     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.115     Document Type: Review

References (168)

1. Whitton JL, Cornell CT, Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism. Nat. Rev. Microbiol. 3(10), 765-776 (2005).
2. Faber HK. Mechanism of infection in poliomyelitis. Am. J. Public. Health Nations Health 23(10), 1024-1030 (1933).
3. Grist N, Bell E. A six year study of coxsackievirus B infection in heart disease. J. Hyg. (London) 73, 165-172 (1973).
4. Grist NR, Bell EJ, Assaad F. Enteroviruses in human disease. Progress in medical virology. Fortschritte der medizinischen Virusforschung. Prog. Med. Virol. 24, 114-157 (1978).
5. Liu Z, Li H, Peng Z, et al. 239 cases of high fever in viral upper respiratory infection (URI) treated with xiang shi qing jie (XSQJ) bag tea. J. Trad. Chinese Med. 16(2), 101-104 (1996).
6. Luo H, Yanagawa B, Zhang J, et al. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J. Virol. 76(7), 3365-3373 (2002).
7. Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74(2), 182-188 (1994).
8. Mena I, Fischer C, Gebhard JR, Perry CM, Harkins S, Whitton JL. Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology. Virology 271(2), 276-288 (2000).
9. National Institutes of Health. The Common Cold. NIAID Fact Sheet. National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, MD, USA (2011).
10. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310(6989), 1225-1229 (1995).
11. Palmenberg AC, Sgro JY. Topological organization of picornaviral genomes: Statistical prediction of RNA structural signals. Semin. Virol. 8(3), 231-241 (1997).
12. Chapman NM, Ragland A, Leser JS, et al. A group B coxsackievirus/ poliovirus 5́ nontranslated region chimera can act as an attenuated vaccine strain in mice. J. Virol. 74(9), 4047-4056 (2000).
13. Harris KS, Xiang W, Alexander L, Lane WS, Paul AV, Wimmer E. Interaction of poliovirus polypeptide 3CDpro with the 5́ and 3́ termini of the poliovirus genome. Identification of viral and cellular cofactors needed for efficient binding. J. Biol. Chem. 269(43), 27004-27014 (1994).
14. Xiang W, Harris KS, Alexander L, Wimmer E. Interaction between the 5́-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication. J. Virol. 69(6), 3658-3667 (1995).
15. Semler BL, Johnson VH, Tracy S. A chimeric plasmid from cDNA clones of poliovirus and coxsackievirus produces a recombinant virus that is temperature-sensitive. Proc. Natl Acad. Sci. USA 83(6), 1777-1781 (1986).
16. Iwasaki A, Welker R, Mueller S, Linehan M, Nomoto A, Wimmer E. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J. Infect. Dis. 186(5), 585-592 (2002).
17. Greve J, Davis G, Meyer A, et al. The major human rhinovirus receptor is ICAM-1. Cell 56, 839-847 (1989).
18. Fricks CE, Hogle JM. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64(5), 1934-1945 (1990).
19. Mcgeady ML, Crowell RL. Proteolytic cleavage of VP1 in 'A' particles of coxsackievirus B3 does not appear to mediate virus uncoating by HeLa cells. J. Gen. Virol. 55(Part 2), 439-450 (1981).
20. Martino TA, Petric M, Weingartl H, et al. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology 271(1), 99-108 (2000).
21. Wang X, Bergelson JM. Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J. Virol. 73(3), 2559-2562 (1999).
22. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165(3), 848-864 (1987).
23. Anderson D, Wilson J, Carthy C, Yang D, Kandolf R, McManus B. Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J. Virol. 70(7), 4632-4645 (1996).
24. Liu P, Aitken K, Kong YY, et al. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat. Med. 6(4), 429-434 (2000).
25. Summers DF, Maizel JV, Jr. Evidence for large precursor proteins in poliovirus synthesis. Proc. Natl Acad. Sci. USA 59(3), 966-971 (1968).
26. Rueckert R. Picornaviruses. Fundamental Virology, 3rd Edition. Fields BN, Knipe DM, Howley PM (Eds). Lippincott-Raven, PA, USA, 477-522 (1996).
27. Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 243(1), 61-73 (2011).
28. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 140(6), 805-820 (2010).
29. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
30. Kemball CC, Alirezaei M, Whitton JL. Type B coxsackieviruses and their interactions with the innate and adaptive immune systems. Future Microbiol. 5(9), 1329-1347 (2010).
31. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089), 101-105 (2006).
32. Hornung V, Ellegast J, Kim S, et al. 5́-triphosphate RNA is the ligand for RIG-I. Science 314(5801), 994-997 (2006).
33. Pichlmair A, Schulz O, Tan CP, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5́-phosphates. Science 314(5801), 997-1001 (2006).
34. Sharma S, Tenoever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 300(5622), 1148-1151 (2003).
35. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122(5), 669-682 (2005).
36. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167-1172 (2005).
37. Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5- mediated type I interferon induction. Nat. Immunol. 6(10), 981-988 (2005).
38. Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18(5), 2986-2996 (1998).
39. Ramos HJ, Gale M, Jr. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr. Opin. Virol. 1(3), 167-176 (2011).
40. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann. NY Acad. Sci. 1143, 1-20 (2008).
41. Kato H, Sato S, Yoneyama M, et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23(1), 19-28 (2005).
42. Ohka S, Igarashi H, Nagata N, et al. Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J. Virol. 81(15), 7902-7912 (2007).
43. Morrison JM, Racaniello VR. Proteinase 2Apro is essential for enterovirus replication in type I interferon-treated cells. J. Virol. 83(9), 4412-4422 (2009).
44. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 327(5963), 291-295 (2010).
45. Luber CA, Cox J, Lauterbach H, et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 32(2), 279-289 (2010).
46. Muzio M, Chinnaiyan A, Kischkel F, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827 (1996).
47. Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat. Rev. Mol. Cell Biol. 12(11), 757-763 (2011).
48. Morizot A, Saleh M. Non-apoptotic functions of cell death effectors in inflammation and innate immunity. Microbes Infect. doi:10.1016/j.micinf.2012.06. 005 (2012) (Epub ahead of print).
49. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (1997).
50. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat. Rev. Immunol. 1, 50-58 (2001).
51. Imanishi T, Murry CE, Reinecke H, et al. Cellular FLIP is expressed in cardiomyocytes and down-regulated in TUNEL-positive grafted cardiac tissues. Cardiovasc. Res. 48(1), 101-110 (2000).
52. Steenbergen C, Afshari CA, Petranka JG, et al. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am. J. Physiol. Heart Circ. Physiol. 284(1), H268-276 (2003).
53. Theofilopoulos A. The basis for autoimmunity: part I, mechanisms of aberrant self-recognition. Immunol. Today 16, 90-98 (1995).
54. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl Acad. Sci. USA 99(2), 637-642 (2002).
55. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19(6), 727-740 (2005).
56. Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J. Virol. 79(20), 12944-12951 (2005).
57. Spiropoulou CF, Ranjan P, Pearce MB, et al. RIG-I activation inhibits ebolavirus replication. Virology 392(1), 11-15 (2009).
58. Sumpter R, Jr, Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79(5), 2689-2699 (2005).
59. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic. polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103(22), 8459-8464 (2006).
60. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS mediate type I interferon responses to coxsackie B virus. J. Virol. 84(1), 254-260 (2010).
61. Huhn MH, McCartney SA, Lind K, Svedin E, Colonna M, Flodstrom-Tullberg M. Melanoma differentiation-associated protein-5 (MDA-5) limits early viral replication but is not essential for the induction of type 1 interferons after Coxsackievirus infection. Virology 401(1), 42-48 (2010).
62. Kato H, Takeuchi O, Mikamo-Satoh E, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205(7), 1601-1610 (2008).
63. Daffis S, Szretter KJ, Schriewer J, et al. 2́-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468(7322), 452-456 (2010).
64. Zust R, Cervantes-Barragan L, Habjan M, et al. Ribose 2́-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor MDA5. Nat. Immunol. 12(2), 137-143 (2011).
65. Le Gall O, Christian P, Fauquet CM, et al. Picornavirales, a proposed order of positive-sense single-stranded RNA viruses with a pseudo-T = 3 virion architecture. Arch. Virol. 153(4), 715-727 (2008).
66. Pelletier J, Kaplan G, Racaniello VR, Sonenberg N. Translational efficiency of poliovirus mRNA: mapping inhibitory cis-acting elements within the 5́ noncoding region. J. Virol. 62(7), 2219-2227 (1988).
67. Pelletier J, Kaplan G, Racaniello VR, Sonenberg N. Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5́ noncoding region. Mol. Cell. Biol. 8(3), 1103-1112 (1988).
68. Belsham GJ, Sonenberg N. RNA-protein interactions in regulation of picornavirus RNA translation. Microbiol. Rev. 60(3), 499-511 (1996).
69. Shiroki K, Ishii T, Aoki T, et al. Host range phenotype induced by mutations in the internal ribosomal entry site of poliovirus RNA. J. Virol. 71(1), 1-8 (1997).
70. Tu Z, Chapman NM, Hufnagel G, et al. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5́ nontranslated region. J. Virol. 69(8), 4607-4618 (1995).
71. Dunn JJ, Chapman NM, Tracy S, Romero Jr. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5́ nontranslated region. J. Virol. 74(10), 4787-4794 (2000).
72. Chapman NM, Kim KS, Drescher KM, Oka K, Tracy S. 5́ terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 375(2), 480-491 (2008).
73. Palmenberg AC, Osorio JE. Cardioviral poly(C) tracts and viral pathogenesis. Arch. Virol. Suppl. 9, 67-77 (1994).
74. Barral PM, Morrison JM, Drahos J, et al. MDA-5 is cleaved in poliovirus-infected cells. J. Virol. 81(8), 3677-3684 (2007).
75. Kovacsovics M, Martinon F, Micheau O, Bodmer JL, Hofmann K, Tschopp J. Overexpression of helicard, a CARD-containing helicase cleaved during apoptosis, accelerates DNA degradation. Curr. Biol. 12(10), 838-843 (2002).
76. Chattopadhyay S, Yamashita M, Zhang Y, Sen GC. The IRF-3/Bax-mediated apoptotic pathway, activated by viral cytoplasmic RNA and DNA, inhibits virus replication. J. Virol. 85(8), 3708-3716 (2011).
77. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10(10), 1065-1072 (2009).
78. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat. Rev. Immunol. 6(3), 196-204 (2006).
79. Sarkar D, Desalle R, Fisher PB. Evolution of MDA-5/RIG-I-dependent innate immunity: independent evolution by domain grafting. Proc. Natl Acad. Sci. USA 105(44), 17040-17045 (2008).
80. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M, Jr. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J. Virol. 82(2), 609-616 (2008).
81. Loo YM, Fornek J, Crochet N, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82(1), 335-345 (2008).
82. Shingai M, Ebihara T, Begum NA, et al. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J. Immunol. 179(9), 6123-6133 (2007).
83. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454(7203), 523-527 (2008).
84. Baltimore D, Becker Y, Darnell JE. Virus-specific double-stranded RNA in poliovirus-infected cells. Science 143(3610), 1034-1036 (1964).
85. Steil BP, Kempf BJ, Barton DJ. Poly(A) at the 3́ end of positive-strand RNA and VPg-linked poly(U) at the 5́ end of negative-strand RNA are reciprocal templates during replication of poliovirus RNA. J. Virol. 84(6), 2843-2858 (2010).
86. Hewlett MJ, Rose JK, Baltimore D. 5́-terminal structure of poliovirus polyribosomal RNA is pUp. Proc. Natl Acad. Sci. USA 73(2), 327-330 (1976).
87. Ambros V, Baltimore D. Purification and properties of a HeLa cell enzyme able to remove the 5́-terminal protein from poliovirus RNA. J. Biol. Chem. 255(14), 6739-6744 (1980).
88. Nomoto A, Kitamura N, Golini F, Wimmer E. The 5́-terminal structures of poliovirion RNA and poliovirus mRNA differ only in the genome-linked protein VPg. Proc. Natl Acad. Sci. USA 74(12), 5345-5349 (1977).
89. Takahasi K, Yoneyama M, Nishihori T, et al. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol. Cell 29(4), 428-440 (2008).
90. Mukherjee A, Morosky SA, Delorme-Axford E, et al. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog. 7(3), e1001311 (2011).
91. Dixit E, Boulant S, Zhang Y, et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141(4), 668-681 (2010).
92. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc. Natl Acad. Sci. USA 106(8), 2770-2775 (2009).
93. Jounai N, Takeshita F, Kobiyama K, et al. The Atg5-Atg12 conjugate associates with innate antiviral immune responses. Proc. Natl Acad. Sci. USA 104(35), 14050-14055 (2007).
94. Camoes F, Bonekamp NA, Delille HK, Schrader M. Organelle dynamics and dysfunction: a closer link between peroxisomes and mitochondria. J. Inherit. Metab. Dis.32(2), 163-180 (2009).
95. Potter JA, Randall RE, Taylor GL. Crystal structure of human IPS-1/MAVS/VISA/ Cardif caspase activation recruitment domain. BMC Struct. Biol. 8, 11 (2008).
96. Saha SK, Pietras EM, He JQ, et al. Regulation of antiviral responses by a direct and specific interaction between TR AF3 and Cardif. EMBO J. 25(14), 3257-3263 (2006).
97. Paz S, Vilasco M, Werden SJ, et al. A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. Cell Res. 21(6), 895-910 (2011).
98. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA 102(49), 17717-17722 (2005).
99. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J. Virol. 83(3), 1299-1311 (2009).
100. Tang ED, Wang CY. MAVS self-association mediates antiviral innate immune signaling. J. Virol. 83(8), 3420-3428 (2009).
101. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146(3), 448-461 (2011).
102. Yasukawa K, Oshiumi H, Takeda M, et al. Mitofusin 2 inhibits mitochondrial antiviral signaling. Sci. Signal. 2(84), ra47 (2009).
103. Castanier C, Garcin D, Vazquez A, Arnoult D. Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep. 11(2), 133-138 (2010).
104. Onoguchi K, Onomoto K, Takamatsu S, et al. Virus-infection or 5́ppp-RNA activates antiviral signal through redistribution of IPS-1 mediated by MFN1. PLoS Pathog. 6(7), e1001012 (2010).
105. West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat. Rev. Immunol. 11(6), 389-402 (2011).
106. Arnoult D, Carneiro L, Tattoli I, Girardin SE. The role of mitochondria in cellular defense against microbial infection. Semin. Immunol. 21(4), 223-232 (2009).
107. Ohta A, Nishiyama Y. Mitochondria and viruses. Mitochondrion 11(1), 1-12 (2011).
108. Griffin DE, Hardwick JM. Regulators of apoptosis on the road to persistent alphavirus infection. Ann. Rev. Microbiol. 51, 565-592 (1997).
109. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons. role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3), 237-249 (2003).
110. Lei Y, Moore CB, Liesman RM, et al. MAVS-mediated apoptosis and its inhibition by viral proteins. PloS One 4(5), e5466 (2009).
111. Li HM, Fujikura D, Harada T, et al. IPS-1 is crucial for DAP3-mediated anoikis induction by caspase-8 activation. Cell Death Differ. 16(12), 1615-1621 (2009).
112. Yu CY, Chiang RL, Chang TH, Liao CL, Lin YL. The interferon stimulator mitochondrial antiviral signaling protein facilitates cell death by disrupting the mitochondrial membrane potential and by activating caspases. J. Virol. 84(5), 2421-2431 (2010).
113. Bedard KM, Semler BL. Regulation of picornavirus gene expression. Microbes Infect. 6(7), 702-713 (2004).
114. Tschopp J, Thome M, Hofmann K, Meinl E. The fight of viruses against apoptosis. Curr. Opin. Genet. Develop. 8(1), 82-87 (1998).
115. Drahos J, Racaniello VR. Cleavage of IPS-1 in cells infected with human rhinovirus. J. Virol. 83(22), 11581-11587 (2009).
116. Barco A, Feduchi E, Carrasco L. Poliovirus protease 3C(pro) kills cells by apoptosis. Virology 266(2), 352-360 (2000).
117. Goldstaub D, Gradi A, Bercovitch Z, et al. Poliovirus 2A protease induces apoptotic cell death. Mol. Cell. Biol. 20(4), 1271-1277 (2000).
118. Yu X, Bi W, Weiss SR, Leibowitz JL. Mouse hepatitis virus gene 5b protein is a new virion envelope protein. Virology 202(2), 1018-1023 (1994).
119. Gonzalez ME, Carrasco L. Viroporins. FEBS Lett. 552(1), 28-34 (2003).
120. Madan V, Castello A, Carrasco L. Viroporins from RNA viruses induce caspase-dependent apoptosis. Cell. Microbiol. 10(2), 437-451 (2008).
121. Belov GA, Romanova LI, Tolskaya EA, Kolesnikova MS, Lazebnik YA, Agol VI. The major apoptotic pathway activated and suppressed by poliovirus. J. Virol. 77(1), 45-56 (2003).
122. Autret A, Martin-Latil S, Mousson L, et al. Poliovirus induces Bax-dependent cell death mediated by c-Jun NH2-terminal kinase. J. Virol. 81(14), 7504-7516 (2007).
123. Yang Y, Liang Y, Qu L, et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl Acad. Sci. USA 104(17), 7253-7258 (2007).
124. Deszcz L, Gaudernak E, Kuechler E, Seipelt J. Apoptotic events induced by human rhinovirus infection. J. Gen. Virol. 86(Pt 5), 1379-1389 (2005).
125. Paulmann D, Magulski T, Schwarz R, et al. Hepatitis A virus protein 2B suppresses beta interferon (IFN) gene transcription by interfering with IFN regulatory factor 3 activation. J. Gen. Virol. 89(Pt 7), 1593-1604 (2008).
126. De Jong AS, De Mattia F, Van Dommelen MM, et al. Functional analysis of picornavirus 2B proteins. effects on calcium homeostasis and intracellular protein trafficking. J. Virol. 82(7), 3782-3790 (2008).
127. Choe SS, Dodd DA, Kirkegaard K. Inhibition of cellular protein secretion by picornaviral 3A proteins. Virology 337(1), 18-29 (2005).
128. Wessels E, Duijsings D, Lanke KH, et al. Effects of picornavirus 3A proteins on protein transport and GBF1-dependent COP-I recruitment. J. Virol. 80(23), 11852-11860 (2006).
129. Blom N, Hansen J, Blaas D, Brunak S. Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Sci. 5(11), 2203-2216 (1996).
130. Campanella M, De Jong AS, Lanke KW, et al. The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis. J. Biol. Chem. 279(18), 18440-18450 (2004).
131. Zaragoza C, Saura M, Padalko EY, et al. Viral protease cleavage of inhibitor of kappaBalpha triggers host cell apoptosis. Proc. Natl Acad. Sci. USA 103(50), 19051-19056 (2006).
132. Pothlichet J, Niewold TB, Vitour D, Solhonne B, Crow MK, Si-Tahar M. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol. Med. 3(3), 142-152 (2011).
133. Saito T, Hirai R, Loo YM, et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl Acad. Sci. USA 104(2), 582-587 (2007).
134. Michallet M-C, Meylan E, Ermolaeva MA, et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 28(5), 651-661 (2008).
135. O'donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol. 17(5), 418-424 (2007).
136. Fitzgerald KA. IKK[epsi] and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491-496 (2003).
137. Gohda J, Matsumura T, Inoue J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)- dependent pathway in TLR signaling. J. Immunol. 173(5), 2913-2917 (2004).
138. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J. Biol. Chem. 280(44), 36560-36566 (2005).
139. Takahashi K, Kawai T, Kumar H, Sato S, Yonehara S, Akira S. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J. Immunol. 176(8), 4520-4524 (2006).
140. Rajput A, Kovalenko A, Bogdanov K, et al. RIG-I RNA helicase activation of IRF3 transcription factor is negatively regulated by caspase-8-mediated cleavage of the RIP1 protein. Immunity 34(3), 340-351 (2011).
141. Sears N, Sen GC, Stark GR, Chattopadhyay S. Caspase-8-mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation. J. Biol. Chem. 286(38), 33037-33044 (2011).
142. Maelfait J, Vercammen E, Janssens S, et al. Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J. Exp. Med. 205(9), 1967-1973 (2008).
143. Lemmers B, Salmena L, Bidere N, et al. Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. J. Biol. Chem. 282(10), 7416-7423 (2007).
144. Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471(7338), 363-367 (2011).
145. O'donnell MA, Perez-Jimenez E, Oberst A, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13(12), 1437-1442 (2011).
146. Kovalenko A, Kim JC, Kang TB, et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J. Exp. Med. 206(10), 2161-2177 (2009).
147. Gunther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 477(7364), 335-339 (2011).
148. Saelens X, Festjens N, Parthoens E, et al. Protein synthesis persists during necrotic cell death. J. Cell Biol. 168(4), 545-551 (2005).
149. Vanden Berghe T, Kalai M, Denecker G, Meeus A, Saelens X, Vandenabeele P. Necrosis is associated with IL-6 production but apoptosis is not. Cell. Signal. 18(3), 328-335 (2006).
150. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 388(6638), 190-195 (1997).
151. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 10(11), 640-648 (2000).
152. Dohrman A, Kataoka T, Cuenin S, Russell JQ, Tschopp J, Budd RC. Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF-kappa B activation. J. Immunol. 174(9), 5270-5278 (2005).
153. Golks A, Brenner D, Krammer PH, Lavrik IN. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J. Exp. Med. 203(5), 1295-1305 (2006).
154. Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386(6624), 517-521 (1997).
155. Field N, Low W, Daniels M, et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell. Sci. 116(Pt 18), 3721-3728 (2003).
156. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199(7), 993-1003 (2004).
157. Challa S, Woelfel M, Guildford M, Moquin D, Chan FK. Viral cell death inhibitor MC159 enhances innate immunity against vaccinia virus infection. J. Virol. 84(20), 10467-10476.
158. Balachandran S, Venkataraman T, Fisher PB, Barber GN. Fas-associated death domain-containing protein-mediated antiviral innate immune signaling involves the regulation of Irf7. J. Immunol. 178(4), 2429-2439 (2007).
159. Handa P, Tupper JC, Jordan KC, Harlan JM. FLIP (Flice-like inhibitory protein) suppresses cytoplasmic double-stranded- RNA-induced apoptosis and NF-kappaB and IRF3-mediated signaling. Cell Commun. Signal. 9, 16 (2011).
160. Huber S, Dohrman A, Sartini D, Budd RC. Reduced myocarditis following Coxsackievirus infection in cellular FLICE inhibitory protein-long form-transgenic mice. Immunology 119(4), 541-550 (2006).
161. Li H, Tang QZ, Liu C, et al. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 56(6), 1109-1117 (2010).
162. Yeh WC, Itie A, Elia AJ, et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12(6), 633-642 (2000).
163. Lee JS, Li Q, Lee JY, et al. FLIP-mediated autophagy regulation in cell death control. Nat. Cell Biol. 11(11), 1355-1362 (2009).
164. Schlegel A, Giddings TH, Jr, Ladinsky MS, Kirkegaard K. Cellular origin and ultrastructure of membranes induced during poliovirus infection. J. Virol. 70(10), 6576-6588 (1996).
165. Jackson WT, Giddings TH Jr, Taylor MP, et al. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol. 3(5), e156 (2005).
166. Taylor MP, Jackson WT. Viruses and arrested autophagosome development. Autophagy 5(6), 870-871 (2009).
167. Feoktistova M, Geserick P, Kellert B, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43(3), 449-463 (2011).
168. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ. 17(6), 942-951 (2010).